| Objectives:Tumor cells are adapted to a high levels of oxidative stress state,which is an important mechanism to maintain cell survival.DJ-1 is a kind of antioxidant stress protein,which plays an important role in the adaptation to oxidative stress.This study examined the concentration of DJ-1 in peripheral blood(PB)of patients with multiple myeloma,and preliminarily analyzed the relationship between DJ-1 and patients' clinical features,laboratory indicators and short-time therapeutic response.Methods:Enzyme-linked Immunosorbent method(Enzyme-linked Immunosorbent Assay,ELISA)was used to detect the DJ-1 concentration in the PB of newly diagnozed(ND)(n = 45),relapsed(n = 10)MM patients and age-matched healthy volunteers(n = 20).Meanwhile,clinical and laboratory information of subjected patients were recorded,and their response to therapies were traced.DJ-1 concentration between MM patients and control was compared,and the correlations of DJ-1 with disease staging(DS and ISS),bone marrow plasma cell percentage(BMPC%),beta2-microglobulin,albumin,creatinine,serum calcium,and lactate dehydrogenase,were analyzed respectively.Also,correlation of DJ-1 with the patients' response to initial treatment was determined.A p value <0.05 was considered statistically significant.Results:1.The ELISA method for Dj-1 detection in the peripheral blood of MM patients was established.2.Peripheral blood Dj-1 concentration in ND-MM patients(n = 45)was significantly higher than that of healthy controls(n = 20)(p < 0.02),and Dj-1 level was higher in relapsed/progressive(R/R)MM patients(n=10)than healthy control(n = 20)(p < 0.05).The Dj-1 level was higher in ND-MM patients(n = 45)than that in R/R patients(n=10)(p < 0.05).3.There was a significant difference in ND-MM patients of different ISS stages in term of the Dj-1 level(p = 0.02).Serum Dj-1 level in IgA patients was significantly higher than that in IgG patients(p < 0.05).The level of Dj-1 in ND-MM patients was positively correlated with the proportion of bone marrow immature plasma cells and beta2-microglobulin(r = 0.378,r = 0.489,p < 0.05),and was negatively correlated with albumin level(r =-0.429,p < 0.05).4.There was no significant difference in serum Dj-1 protein level in ND-MM of different D-S stages(p = 0.968,p > 0.05).There was no significant correlation between PB DJ-1 level with light chain type(? vs ?)(p = 0.338,p > 0.05),and with age,lactate dehydrogenase,serum calcium,hemoglobin,bone lesion(r = 0.72,r = 0.185,r = 0.076,r = 0.089,r = 0.29,r = 0.041,p > 0.05).5.The median value of DJ-1 was 2.7ng/ml,which was used as the cut-off valule for analysis,and the treatment response of patients was followed up.Our study showed that patients with DJ-1 ?2.7ng/ml required longer duration to achieve partial remission(PR)than patients with Dj-1 < 2.7ng/ml.After 4 cycles of chemotherapy,univariate analysis showed that the proportion of patients who achieved at least partial response(PR)were higher in patients with Dj-1<2.7ng/ml than in Dj-1?2.7ng/ml(71.4% vs 37.5%,p = 0.037).Conclusions:1.Newly diagnosed multiple myeloma patients have an abnormally increased DJ-1 level in the peripheral blood,suggesting that myeloma cells are in a higher oxidative stress state,and can be reflected in peripheral blood.2.There is a correlation between Dj-1 level and tumor burden in patients with newly diagnosed multiple myeloma,and the tumor burden of patients with high Dj-1 level was higher.3.The short-time response is worse in multiple myeloma patients with higher Dj-1 level,suggesting that Dj-1 may be a biomarker related to the prognosis,which deserves further studies. |
PDF Full Text Request